Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore exercitation ullamco…
Race Against Time Slide 1

The U.S. population is about 328 million people1

The U.S. population is about 328 million people1

The U.S. population is about 328 million people1

Race Against Time Slide 2

30 million of these have diabetes1

30 million of these have diabetes1

30 million of these have diabetes1

Race Against Time Slide 3

2.9 million of those with diabetes suffer from chronic wounds1

2.9 million of those with diabetes suffer from chronic wounds1

2.9 million of those with diabetes suffer from chronic wounds1

previous arrow
next arrow

A Race Against Time

Health professionals know this race all too well, as they strive to save the lives and limbs of people with diabetes suffering from severe wounds. We are addressing this critical need by providing advanced treatments that help promote healing and offer protection, even in difficult and challenging situations.

This pressing need, touching millions of families, is why our energies are focused on wound care. Our passion to help and heal – together with our advanced treatments – envisions a future when more patients will be treated and better outcomes will result.

For all of us at MiMedx, waiting is not an option.

When it comes to wound care, our goal is to help patients heal as quickly as possible.

About MiMedx

MiMedx is an industry leader in advanced wound care utilizing human placental-based tissue allografts. Products including EpiFix and EpiCord have been used in the treatment of wounds such as Diabetic Foot Ulcers (DFUs) and Venous Leg Ulcers (VLUs).

What Are Human Placental-Based Tissue Allografts?

Placental tissue is donated by healthy consenting mothers undergoing scheduled C-sections and delivering a live birth. All tissue donors are tested for infectious diseases, similar to the testing done for blood donation. The tissue undergoes our patent-protected process to preserve the inherent growth factors, providing an easy to use, clinically effective graft to aid in wound healing.

How are the allografts used to treat Diabetic Foot Ulcers (DFUs) and Venous Leg Ulcers (VLUs)?

You and your doctor may consider placental-based allografts as a treatment option if you have been diagnosed with a chronic wound that has not responded to Standard Care (SC) and it is time to move to a more advanced therapy. EpiFix and EpiCord have demonstrated the following clinical results:

  • 94% of DFU patients treated with EpiFix remained healed 9-12 months after initial closure2
  • 81% of DFU patients treated with EpiCord plus SC had complete healing by 12 weeks3
  • 60% of VLU patients treated with EpiFix plus SC had complete wound closure at 12 weeks vs 35% treated with SOC alone4,5

CONTACT US FOR MORE WOUND HEALING INFORMATION: 866.477.4219

References:

  1. SmartTRAK / BioMedGPS, LLC . Accessed October 1, 2019.
  2. Zelen, et al. Wound Medicine. 2014 Feb;4:1-4.3.
  3. Tettelbach, et al. Int Wound J. 2018;1–9.
  4. Bianchi, et al. Int Wound J 2017; doi: 10.1111/iwj.12843.
  5. Bianchi C, et al. Int Wound J. 2019; 16: 761– 767.

SB831.001